Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…Abstract Number: 0029 • ACR Convergence 2023
Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts
Background/Purpose: Cellular interactions between alveolar macrophages (MΦ) and human lung fibroblasts (HLFs) contribute to excessive pro-inflammatory and pro-fibrotic responses in rheumatoid arthritis interstitial lung disease…Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…Abstract Number: 0770 • ACR Convergence 2023
Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes
Background/Purpose: Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix remodeling that have been implicated in the pathogenesis and progression of rheumatoid arthritis (RA) and…Abstract Number: 1156 • ACR Convergence 2023
Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune diseases with cutaneous, musculoskeletal, and systemic involvements. The Hong Kong Myositis Registry (MyoHK) was…Abstract Number: 1514 • ACR Convergence 2023
Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in connective tissue disorders (CTD) including rheumatoid arthritis, scleroderma and inflammatory myopathies.…Abstract Number: 1944 • ACR Convergence 2023
Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre
Background/Purpose: Interstitial lung disease (ILD) comprises a wide range of disorders categorized by clinical, radiographic and pathologic findings that is closely associated with autoimmune connective…Abstract Number: 2365 • ACR Convergence 2023
Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression
Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation…Abstract Number: 0093 • ACR Convergence 2023
Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…Abstract Number: 0619 • ACR Convergence 2023
Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review
Background/Purpose: There is no established consensus on defining the clinical course and the outcomes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), both among experts and…Abstract Number: 0771 • ACR Convergence 2023
A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis
Background/Purpose: Based on the overlap in peripheral blood biomarkers associated with rheumatoid arthritis interstitial lung disease (RA-ILD) and idiopathic pulmonary fibrosis (IPF), a composite biomarker…Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…Abstract Number: 1531 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): A TriNetX Database Study
Abstract Number: 1948 • ACR Convergence 2023
The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD), prevalent in Idiopathic Inflammatory Myositis (IIM) patients, significantly impacts prognosis. Certain myositis-specific antibodies, including anti-MDA5 and anti-aminoacyl-tRNA synthetases (ARS), are…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 39
- Next Page »